No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LH240719C220000
- 0.90
- +0.58+181.25%
15min DelayClose Jul 16 15:59 ET
0.90High0.90Low
0.90Open0.32Pre Close11 Volume863 Open Interest220.00Strike Price990.00Turnover37.62%IV2.03%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.90Extrinsic Value100Contract SizeAmericanOptions Type0.3231Delta0.0504Gamma146.78Leverage Ratio-0.5032Theta0.0052Rho47.43Eff Leverage0.0680Vega
Intraday
- 5D
- Daily
News
Barclays Maintains Labcorp Holdings(LH.US) With Hold Rating, Maintains Target Price $213
Barclays analyst Stephanie Davis maintains $Labcorp Holdings(LH.US)$ with a hold rating, and maintains the target price at $213.According to TipRanks data, the analyst has a success rate of 41.5%
Barclays Reaffirms Their Hold Rating on Laboratory (LH)
In a report released today, Stephanie Davis from Barclays maintained a Hold rating on Laboratory (LH – Research Report), with a price target of $213.00. The company’s shares closed yesterday at $207.49.
These 4 Measures Indicate That Labcorp Holdings (NYSE:LH) Is Using Debt Extensively
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about
Express News | Labcorp Holdings Inc : UBS Cuts Target Price to $260 From $262
Morgan Stanley Maintains Labcorp Holdings(LH.US) With Buy Rating, Maintains Target Price $260
Morgan Stanley analyst Erin Wright maintains $Labcorp Holdings(LH.US)$ with a buy rating, and maintains the target price at $260.According to TipRanks data, the analyst has a success rate of 64.1%
Citi Upgrades Illumina, Quest, Agilent to Buy, Downgrades Avantor
Comments
The company's stock seems overpriced compared to its peers, suggesting limited potential for further growth. Its low beta indicates it may not align with industry levels soon.
Insider selling shares below current price suggests contentment with lower valuation. Lack of insider buying and low insider ownership make the company a cautious investment choice.
Investors' optimism about Laboratory Corporation's performance could lead to inflated stock prices. The high share price puts existing and new shareholders at potential risk, possibly paying an unnecessary premium.
Labcorp's acquisition set to fortify its Massachusetts presence and push its goal of broadening cost-effective lab testing. The partnership with Baystate Health aims at promoting efficient, advanced healthcare services and improving patient and provider experience.
Read more